Search

Symptom-related distress among indigenous Australians in specialist end-of-life care: Findings from the multi-jurisdictional palliative care outcomes collaboration data

These findings provide reassurance of reasonable equivalence of end-of-life outcomes for Indigenous patients who have been accepted for specialist palliative care

Factors Associated With 90-Day Readmission After Stroke or Transient Ischemic Attack: Linked Data From the Australian Stroke Clinical Registry

Apart from comorbidities and patient-level characteristics, readmissions after stroke/transient ischemic attack were associated with discharge destination

General practitioners’ perceptions of their communication with Australian Aboriginal patients with acquired neurogenic communication disorders

GPs report difficulty recognising acquired communication disorders and their lack of prioritising assessment and treatment of communication ability after brain injur

Delay in commencement of palliative care service episodes provided to Indigenous and non-Indigenous patients

Although the timeliness benchmark is being met for Indigenous Australians in palliative care, they may experience delayed initiation of care episodes

Secondary preventive medication use in a prevalent population-based cohort of acute coronary syndrome survivors

Longer time since last acute coronary syndrome admission was associated with dispensing fewer medications types and combinations in 2008

Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal

The impact of the 23vPPV booster on IPD incidence among Australian Indigenous children is unclear from regional reports of small case numbers.

Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.

Background: High incidence and serotype diversity of invasive pneumococcal disease (IPD) in Indigenous children in remote Australia led to rapid introduction of

New childhood brain tumour drugs to be tested

It is the kids he treats in his role as a paediatric oncologist that motivate Dr Nick Gottardo in his work as a The Kids Research Institute Australia cancer researcher.

The NICE GUT Trial

Tom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,

Carol's story: losing a parent to RHD

After being diagnosed with rheumatic heart disease at ten, Elizabeth had to leave country and her family for a large chunk of her childhood so she could be treated in Adelaide.